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Summary Even though many studies suggest that proteoglycans with their structurally determinative
polysaccharide chains, the glycosaminoglycans (GAGs), are important mediators of cellular interactions, little
is known about expression and possible functions of these macromolecules expressed by tumour cells during
the transition from low to highly metastatic behaviour. Therefore, we investigated the cellular expression and
secretion of GAGs in a syngeneic tumour system of DBA/2 mice consisting of a methylcholanthrene-induced
low metastatic T lymphoma (Eb), its highly metastatic spontaneous variant (ESb), and a low metastatic
derivative of ESb (ESb-MP), selected by its adherent growth properties. The [35S]-sulphate-labelled GAGs
were isolated from in vitro cultivated cells and further characterized by separation on Sepharose CL 6B, on
Mono-Q ion exchange chromatography, and alkali- and enzymatic digestion. In contrast to Eb-cells which
produce chondroitin/dermatan sulphate (CS/DS) and heparan sulphate (HS) (cellular extract: CS/DS 67%,
HS 33%; culture medium: CS/DS 61%, HS 39%) ESb- and ESb-MP-cells only express and secrete CS/DS.
For ESb cells the CS portions consisted of 42% chondroitin-4-sulphate (CS-4) and 58% chondroitin-6-
sulphate (CS-6), for ESb-MP cells of 23% CS-4 and 77% CS-6, for Eb cells of 16% CS-4 and 84% CS-6. The
cell surface GAGs of the adherent variant ESb-MP contained a significantly higher portion of DS (65%)
compared to ESb cells (25%). GAGs of all tumour cell lines studied had a mol. wt ranging from 35-40kD
compared to GAG molecular weight standards. Ion exchange chromatography indicated that differences in
charge density between GAGs of these cell lines were minimal. These findings suggest that the different
biological behaviour of the cell lines cannot be attributed to altered size and charge density of their GAG
chains. However, highly metastatic ESb-cells secreted significantly more GAG than low metastatic Eb- and
ESb-MP-cells. The possible consequences of the enhanced secretion of CS/DS by ESb-cells are discussed in
terms of the postulated role of CS/DS in cellular adhesion, growth regulation and interactions with the
immune system.
GAGs, the highly anionic sulphated polysaccharide chains of
proteoglycans, have been associated with the regulation of
cellular interactions, such as cell-cell recognition (Landner et
al., 1982), cell-substrate adhesion (Cole et al., 1985;
Stamatoglou & Keller, 1983), growth control (Fritze et al.,
1985) and masking of cell surface receptors (Fransson et al.,
1984). Their ubiquitous expression on the cell surface and in
peri- and extracellular spaces suggest that they might play a
role in neoplasia and tumour progression (for review see
lozzo, 1985). From the data available at the moment it
seems that there is not one alteration of proteoglycan
expression which is common to all histologically different
tumours but rather that each tumour class bears its own
characteristic deviations of proteoglycans compared to its
normal equivalent.
Surprisingly little is known about alterations of expression
and secretion of tumour cell proteoglycans/GAGs during the
transition of low to highly metastatic capacity. Theoretically,
these macromolecules could be involved in several steps of
the metastatic cascade: (1) The attachment of tumour cells to
the basement membranes of blood vessels and host tissue
borders could be influenced by altered expression of proteog-
lycans, (2) secreted proteoglycans of tumour cells could
impair the growth of vascular smooth muscle cells thus
facilitating the extravasation process, (3) proteoglycans/
GAGs secreted by tumour cells could modulate functions of
immune cells and serum components during tumour cell
transportation in the blood circulation. Indications for these
postulated functions of GAGs have been obtained already.
For instance, a high binding capacity of heparan sulphate to
fibronectin and collagen, important components of basement
membranes, has been described (Laterra et al., 1983; Spiro &
Parthasarathy, 1982). Furthermore, an antiproliferative effect
of heparan sulphate on aortic smooth muscle cells has been
reported (Fritze et al., 1985), GAGs may influence the
Correspondence: R. Schwartz-Albiez.
Received 10 July, 1987; and in revised from 18 January, 1988.
regulation of haemopoiesis (Spooncer et al., 1983) and finally,
chondroitin sulphate in human serum is able to bind Clq,
reducing the complement-activating properties of this mole-
cule (Silvestri et al., 1981).
Since there are no data available of the proteoglycan/
GAG profiles of tumour cells differing in their metastatic
behaviour, we now analyzed expression and secretion of the
GAGs of three related mouse tumour cell lines, a low
metastatic T lymphoma (Eb), its highly metastatic variant
(ESb) and a low metastatic derivative of ESb (ESb-MP)
selected for its adherent growth properties. These tumour
lines have been extensively investigated concerning their
invasive capacity (Schirrmacher et al., 1979b), their immuno-
genicity and tumour-associated transplantation antigens
(Schirrmacher et al., 1979a) and their differentiation antigens
(Altevogt et al., 1982). The glycoproteins and glycolipids of
cell lines Eb and ESb have been described in two preceding
studies (Schwartz et al., 1984; Schwartz et al., 1985). In the
present work, we demonstrate that GAGs from highly
metastatic ESb cells are essentially different compared to
those from low metastatic Eb cells. Heparan sulphate, which
is found on most mammalian cells, is present on Eb- but not
on ESb-cells. There is also some variation in the GAG
pattern between cell line ESb and its low metastatic, adher-
ent derivative ESb-MP. However, secretion of GAGs seems
to be enhanced in the highly metastatic ESb cell line.
We assume, also in view of our findings for glycoprotein
and glycolipid changes in this tumour system, that the
process towards increasing metastatic capacity coincides with
complex alterations in all cell surface expressed
glycoconjugates
Materials and methods
Materials
The following materials were used in this study: [35S]-sulfuric
acid (carrier free) from New England Nuclear (Boston, MA,
Br. Cancer (1988), 57, 569-575570 R. SCHWARTZ-ALBIEZ et al.
USA); [3H]-glucosamine from Amersham and Buchler
(Braunschweig, FRG); Bio-Gel P60 (100-200 mesh) from
Bio-Rad (Richmond, CA, USA); Sepharose CL-6B, Sepha-
dex G-50 and G-25 and a Mono Q HR 5/5 column from
Pharmacia (Uppsala, Sweden); Chondroitinase ABC and AC
from Sigma (St Louis, MO, USA), Heparinase and Hepariti-
nase from Seikagaku (Tokyo, Japan); Hyaluronate lyase
(prepared from Streptomyces hyaluronilyticus) from Calbio-
chem (San Diego, CA, USA); Pronase P from Serva (Heidel-
berg, FRG). GAG molecular weight standards were from a
preparation, described by Stuhlsatz et al., 1981, and were a
generous gift from Dr Stuhlsatz (Aachen, FRG).
Cell lines and culture conditions
The origin, history and characteristics of the parental
tumour line L5178YE (=Eb) and its variant L5178YES
(=ESb) have been described elsewhere (Schirrmacher et al.,
1979a,b) In addition, a low metastatic variant of ESb, ESb-
MP, was used which was selected from ESb cultures by its
plastic-adherent growth characteristic in vitro (Benke et al.,
1988; Fogel et al., 1983). Eb and ESb-cells are dis-
tinguished from each other by their specific expression of
differentiation antigens (Altevogt et al., 1982), tumour-asso-
ciated transplantation antigens (TATA) (Schirrmacher et al.,
1979a) and cell surface glycoconjugates (Schwartz et al.,
1984, Schwartz et al., 1985) whereas the variant ESb-MP is
more closely related to ESb. Both cell types express identical
differentiation antigens and TATA (Fogel et al., 1983). All
tumour cell lines were cultivated in RPMI 1640 medium
(Gibco Biocult, Glasgow, Scotland) containing 10% foetal
calf serum (Gibco) and 2mM glutamine. In the case of ESb-
cells additionally 5 x 10-5M 2-mercaptoethanol was added.
Cell lines Eb and ESb grow in suspension, the adhesive ESb-
MP-cells were brought into suspension by short treatment
with a 0.2% EDTA solution in PBS. All cell lines were
routinely screened for absence of mycoplasms according to
Kucherlapati et al. (1975).
Labelling of cells and isolation of 35S-labelled material
For metabolically labelling, exponentially growing cells of in
vitro cultures were harvested, washed in sulphate-deficient
medium (Gibco) and were adjusted to a concentration of
5 x 107 cells/25ml sulphate-deficient medium containing
additionally 5% foetal calf serum, 2mM glutamine and
25mM HEPES, to which 2mCi carrier-free [35S]-sulphuric
acid (30-43Cimg) was added and incubation was continued
for 24h at 37°C in a 5% CO2 atmosphere. In some
experiments, cells were additionally labelled with 300,uCi of
D-6-(3H)-glucosamine hydrochloride (23 Ci/mmole). Viability
of the cell cultures after the labelling period was over 95%
as measured by the trypan blue exclusion test. After incuba-
tion, the medium was collected, centrifuged and stored until
further isolation procedures. The cells were washed twice in
PBS; for solubilization, the cells were resuspended in 5ml
distilled water, sonicated and the cell lysates were subse-
quently centrifuged in a SW 50 rotor in a Sorvall centrifuge
at 10,000g, at 40C for 20min. More than 95% of the high
molecular [35S]-labelled material remained in the
supernatant.
The adherent ESb-MP cells were incubated with [35S]_
sulphuric acid as described above, washed 10 times with
icecold RPMI-medium, detached by scrapping off with a
rubber policeman. To remove remaining adherent cells, the
culture flasks were further incubated with 0.25% (w/v)
EDTA. Both suspensions were pooled and cells were pro-
cessed as described above. The material still remaining on
the culture flask bottom was dissolved in 7 M urea,
0.1 MTris/HCl, 2% (w/v) SDS pH 7.2 and desalted on Bio-
Gel P60 as described below. This treatment should release all
extracellular matrix (ECM) material according to Gries-
macher et al., 1987; Keller et al., 1987. For fl-elimination,
lyophilized culture media and the 10,000g supernatants from
the labelled cells were adjusted to 0.5MNaOH with
10M NaOH, incubated at 40 C for 12h and chromatographed
on Bio-Gel P60 (60x 1.4cm) in 0.5MNH4HCO3, 1 mM
EDTA. Fractions of 2ml were collected at 15mlh 1 and
analyzed for radioactivity. Void volume fractions were
pooled as indicated in Figure 1 and lyophilized.
Characterization of isolated GAG
The lyophilized extracts both of cells and culture media were
resuspended in 2ml of 50mM Tris/HCl, pH7.5 and subjected
with and without proper specific enzymatic treatment both
to gel filtration on Sepharose CL 6B and to ion exchange
chromatography on Mono Q.
Extracts were treated with i) Chondroitinase ABC or
Chondroitinase AC (for both enzymes: 1 unit/80,000cpm
[35S]-labelled material; or ii) in combined form with Hepari-
tinase/Heparinase (for both enzymes: 0.5 units/80,000cpm
[35S]-labelled material. Enzyme treatment was for 4h at 37°C
in an incubation buffer containing 0.1 M NaCl, 0.05M Tris/
HCl, pH7.5 for chondroitinase ABC/AC treatment additio-
nally with 1 mM EDTA and for heparitinase treatment with
2mm CaCl2. After enzymatic treatment samples were boiled
and subjected to chromatography. Gel filtration was per-
formed on a Sepharose CL 6B column (60 x 0.8cm) and
Sephadex G-50 (30 x 0.5cm) in 0.15M Tris/HCI buffer,
pH7.5, fractions of 600pl at a flow rate of 9mlh-1 (Sephar-
ose CL 6B) and fractions of 160 1l at a flow rate of
750y1h-1 (Sephadex G-50) were collected and assayed for
radioactivity in a liquid scintillation counter. For estimation
of the molecular size we applied GAG molecular standards
to CL 6B chromatography. FPLC ion exchange chromato-
graphy was done with a Mono Q HR 5/5 column (1 ml
volume) using the LCC-500 controller (Pharmacia) in O.IM
Tris/HCI, pH 7.5 with a linear gradient from 0 to 1 M NaCl
in 45min (flow rate lmlmin-1) as indicated in Figure 4.
Fractions of 1 ml were collected and assayed for radioactivity
in a liquid scintillation counter. The CS-4/CS-6 ratio was
estimated by HPLC (Bruker, Bremen, FRG) of the unsatur-
ated disaccharides (Greiling et al., 1984).
Isolation and analysis of GAGs, as described here, was
performed three times for all tumour lines studied. Incor-
poration of [35S]-sulphate into GAGs and the respective
ratio of cellular to secreted GAGs differed only minimal for
the cell lines in these experiments. Variation in elution
profiles (Kay-values) of the characterized GAGs was less than
10%. In this paper, results of an isolation procedure are
presented in which GAGs of cell lines Eb, ESb and ESb-MP
were prepared at the same time with the same specific
activity of the radionucleotides. In some experiments
[35S]-labelled GAGs of Eb and ESb cells were isolated by
extensive digestion with Pronase P (Serva, Heidelberg, FRG)
instead of P-elimination. In successive Sepharose CL 6B
chromatography before and after specific enzymatic treat-
ment the same distribution of GAGs as described here was
obtained (data not-shown).
Results
Synthesis and secretion of GAG
In a first purification step [35S]-labelled material obtained
from the cellular 10,000 x g supernatants and the culture
media was subjected to f-elimination to separate GAG
chains from the protein core of the respective proteoglycans
and was subsequently run over a Bio-GelP-60 column. Free
GAG chains eluted as distinct peaks in the VO of this column
as shown for the example in Figure 1 (cell line Eb).
These crude GAG preparations were taken to assess the
overall amount of GAGs synthesized and secreted by the cell
lines studied. Table I represents a comparison of the GAG
distribution in the 3 cell lines. The adherent cell line ESb-MP
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Figure 1 Separation of cellular and culture medi
from lower molecular weight glycopeptides and deE
Gel P60 chromatography. Elution profiles of crud
GAG material derived from Eb cells after f3-elimina
P60. (a) profile of cellular material, (b) profile of n
corresponding 24h culture medium. Arrows indica
tran) and Vt (phenol red) of the column. Brack
fractions of the chromatography which were pool
further characterization of GAGs. Elution profiles o
MP-cells ran identical.
secreted smaller amounts of GAGs than the
lines. Quite strikingly, the highly metastatic
secreted more than twice as much GAGs tha
metastatic cell lines.
Since adherent cells are likely to produce an
ing proteoglycans we analyzed the subcellular
ial of ESb-MP cells for its content of [35S]-lab
material by the method of Griesmacher et al..
not observe any ECM-associated proteoglyca
Since it has been suggested that proteoglyc
coupled to the proliferation activity of cell
optimum in the logarithmic growth phase (H
1986) we always used exponentially growing
experiments.
Analysis of cell-bound and secreted GAGs
The [35S]-labelled GAGs from each cell lino
identified by their susceptibility to selective I
either chondroitinase AC lyase (degrading CS-
chondroitinase ABC lyase (degrading DS in ad
and CS-6), or heparinase/heparitinase (degradii
HS respectively). The enzymatically treated
GAG fractions were first chromatographed on
6B as shown in Figure 2. Untreated GAG ch
remaining intact after specific enzymatic treatr
with a Ka, ranging from 0.43 to 0.57. Effec
treatment resulted in an increased elution of r
the V, of the column, intermediate degradation products were
not observed.
Cellular and secreted GAGs of tumour line Eb were
totally digested by a sequential treatment with chondroiti-
nase ABC and heparitinase/heparinase (data not shown). In
individual degradation experiments cellular GAGs of Eb-cells
were shown to be 67% degradable by chondroitinase ABC
and to 33% by heparitinase/heparinase (Figure 2A). The
heparan sulphate chains with a Kay of 0.47 were slightly
larger than the chondroitin sulphate chains with a Ka, of 0.5.
Similar results were obtained for the secreted GAGs of Eb-
cells (Figure 2B), 61% of the radioactivity running in the
peak fraction were susceptible to degradation by chondroiti-
nase ABC and 39% to degradation by heparitinase/hepari-
nase. Again, heparan sulphate chains (Ka, =0.43) were
slightly larger than chondroitin sulphate chains (Kay =0.53).
40 50 Following chondroitinase AC digestion the V, material of the
Sepharose CL-6B chromatography was rechromatographed
on Sephadex G-50 (Figure 3). The material which is excluded
ia-derived GAGs or partially included represents DS oligosaccharides. The
salting over Bio- elution profiles of the oligosaccharides from cellular and
le, [ S]-labelled secreted GAGs of Eb and ESb cells were almost identical.
ation on Bio-Gel We could estimate that both Eb and ESb cellular GAGs
ter thludex- contain approximately 25% DS copolymeric to CS in con-
;ets includes the trast to ESb-MP cellular GAGs which contain approximately
ed and used for 65% DS copolymeric to CS. The unsaturated disaccharides
of ESb- and ESb- in the V, of the Sephadex G-50 chromatography were
investigated for sulphation in the 4- and 6-position of
GaINAc by the method of Greiling et al. (1984): Eb cells,
two other cell 16% CS-4 and 84% CS-6; ESb cells, 42% CS-4 and 58%
cell line ESb CS-6; ESb-MP cells, 23% CS-4 and 77% CS-6.
In the two low In contrast to cell line Eb, cellular and secreted
[35S]-labelled GAGs of cell lines ESb and ESb-MP were
ECM contain- totally degradable by chondroitinase ABC (Figure 2C-F),
matrix mater- demonstrating that these two cell lines only produce CS/DS.
elled polymeric The CS chains varied in their size to minor extents (ESb:
1987. We did cellular form (Kav=0.5), secreted form (K.,=0.53); ESb-MP:
ns.
cellular form (Kav
= 0.47), secreted form (Kav
= 0.57). Since in
an synthesis is most cell systems studied that far, the predominant GAG
s being at its component of the cell surface seems to be HS - only few cells
ollmann et al., like lymphocytes display a propensity towards cell surface
cells for these expressed CS (Capeau et al., 1978; Levitt & Ho, 1983) the
exclusive production and expression of CS/DS in ESb- and
ESb-MP-cells seems to be a rather unique event. Moreover, it
points to a close relationship of these two cell lines and to a
more distant relationship between these two cell lines and
cell line Eb.
e were further The chain size of the GAGs derived from Eb-, ESb- and
treatment with ESb-MP-cells was compared to corneal keratan sulphate and
4 and CS-6) or chondroitin sulphate molecular weight standards (Stuhlsatz
Idition to CS-4 et al., 1981) and was determined to range between 35 to
ng heparin and 40kD. All 3 cell lines studied did not seem to produce the
and untreated non-sulphated GAG hyaluronic acid since GAG peak func-
Sepharose CL tions additionally labelled with [3H]-glucosamine did not
ains and those show a reduction in radioactivity after treatment with hya-
ment, migrated luronate lyase from streptomyces (data not shown).
tive enzymatic In control experiments, [35S]-labelled material prior to
radioactivity in #-elimination - to conserve the intact proteoglycans - was
Table I Percentage distribution of [35S]-labelled GAG in cellular extracts and culture
mediaa
Cellular extracts Culture media Total cpm 6
Exp. Cell line %(cpm) %(cpm) cells
1 Eb 82 (15,416) 18 (3,384) 18,800
ESb 64 (23,680) 36 (13,320) 37,000
ESb-MP 87 (35,670) 13 (5,330) 41,000
2 Eb 80 (18,880) 20 (4,620) 23,500
ESb 61 (24,470) 39 (15,730) 40,200
ESb-MP 84 (36,210) 16 (6,790) 43,000
3 Eb 78 (13,060) 22 (3,640) 16,700
ESb 68 (20,170) 32 (9,330) 29,500
ESb-MP 82 (27,190) 18 (6,010) 33,200
aCounts and percentage of distribution were calculated from radioactivity eluting in the
void volume of the Bio-Gel P60 chromatography Figure 1).
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Figure 2 Chromatograph on Sepharose CL 6B. Elution profiles [35S]-labelled GAGs derived from the pooled void volume peak
of the Bio-Gel P60 chromatography (Figure 1) with and without specific enzymatic treatment. Eb cells (a) and culture medium (b),
ESb cells (c) and culture medium (d) and ESb-MP cells (e) and culture medium (f) GAGs were applied to the column in portions of
200-300l (20,000cpm). Recovery of radioactive material was 87-94%. Untreated GAGs (@-@), GAGs treated with
chondroitinase ABC (A-A) and GAGs treated with heparitinase/heparinase (U U). V0 and V, are marked with an arrow.
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Figure 3 Chromatography on Sephadex G-50. V, material of the
Sepharose CL-6B chromatography following chondroitinase AC
digestions (see Figure 2) of GAGs was rechromatographed on
Sephadex G-50. Examples are given for cellular ESb-MP GAGs
(a) and ESb GAGs (b). Arrows indicate VO and V,.
also applied to the Sepharose CL 6B chromatography with
and without further enzymatic treatment. In these experi-
ments peaks migrated closer to the V0 of the column than
the respective peaks of single GAG chains (data not pre-
sented) demonstrating that in all three cell lines studied
GAGs were cell-expressed and secreted in proteoglycan form.
In a next step [35S]-labelled GAGs were further character-
ized by their elution profiles on Mono Q ion exchange
chromatography (Figure 4). CS chains of all three tumour
lines eluted as a peak between 0.9 and 1.OM NaCl, whereas
HS from Eb-cells eluted between 0.8 and 0.9M NaCl. These
results indicate that CS of all three cell lines seem to have a
similar charge density.
Discussion
The role of proteoglycans/GAGs produced by tumour cells
in malignant growth control is still unknown. In a series of
papers differences in the production and composition of
proteoglycans have been discovered in SV-40 virus - trans-
formed 3T3-cells compared to their non-transformed
counterparts (Keller et al., 1980; Underhill & Keller, 1975;
Winterbourne & Mora, 1981).
These authors primarily found a transformation-associated
decrease in O-sulphation of cellular expressed proteoheparan
sulphates and a decreased self-association ability of HS in
transformed cells of this tumour system (Fransson et al.,
1981). It was suggested that these alterations may influence
the interaction of HS with other molecules on the cell
surface or in the extracellular matrix since it is known that
cell-substratum adhesion is partially due to protein-HS inter-
actions (Cole et al., 1985). In particular, cell surface HS
mediates adhesion to fibronectin (Laterra et al., 1983; Sta-
matoglou & Keller, 1983). Similar differences in HS synthesis
were observed by comparison of normal hepatocytes and
hepatoma cells (Robinson et al., 1984).PROTEOGLYCANS OF LOW AND HIGHLY METASTATIC MURINE LYMPHOMAS 573
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Figure 4 FPLC ion exchange chromatography on Mono Q.
(35S)-labelled GAGs derived from the pooled void volume frac-
tions of the Bio-Gel P60 chromatography (Figure 1) were applied
with and without enzymatic treatment in portions of 500lp
(15,000cpm) to the column. Chromatography was performed as
described in Materials and methods. Eb cells (a) and culture
medium(b), ESb cells (c) and culture medium (d), ESb-MP cells
(e) and culture medium (f); Untreated GAG (0-0), GAG
treated with chondroitinase ABC (A-A) and GAG treated with
heparitinase/heparinase (0-0). The broken line represents the
gradient from 0 to 1 M NaCl.
In order to study the changes of proteoglycan synthesis
which may occur during the transition of low to highly
metastatic tumour cells, we analyzed the expression and
secretion of GAGs of the Eb/ESb-tumour system which
consists of cells with different metastatic capacity. Three
major observations were made: 1) the cell line ESb and its
closely related variant ESb-MP were deficient in producing
proteoheparan sulphate in contrast to the parental line Eb,
2) when comparing metastatic behaviour with proteoglycan
metabolism the highly metastatic ESb-cells had a signifi-
cantly higher percentage of secreted proteoglycans than
weakly metastatic Eb- and ESb-MP-cells and 3) cell lines
ESb and ESb-MP differed markedly in their composition of
CS in that cell line ESb-MP contained more CS-6 and CS-4
and DS compared to cell line ESb.
In particular, secretion of proteochondroitin sulphate of
ESb-cells was 4 fold increased compared to Eb- and 2.5 fold
to ESb-MP-cells.
Although the exclusive synthesis of proteochondroitin sul-
phate in ESb- and ESb-MP-cells is an interesting and rarely
occurring phenomenon in mammalian cells, only the
increased secretion of proteochondroitin sulphate can dir-
ectly be correlated to the metastatic capacity of the cells. The
secretion of proteoglycans was lower in the two weakly
metastasizing cell lines of the tumour system which differ
otherwise largely in growth behaviour and surface antigen
expression (Fogel et al., 1983). Apparently, differences in
charge density of HS as described for the 3T3 cell system are
not likely to account for the differences in malignancy of the
Eb/ESb system. Concomitantly with the absence of proteo-
heparan sulphate synthesis ESb-cells produce and secrete a
HS degrading endoglycosidase in contrast to Eb-cells. This
enzyme has been implicated with the facilitated transgression
of the extracellular matrix by metastatic ESb-cells compared
to Eb-cells (Vlodavsky et al., 1983). It seems to be unlikely
that the absence of HS in ESb-cells is caused by the
simultaneous action of the endoglycosidase. ESb-MP-cells
derived directly from ESb-cell cultures also produce only CS
but do not produce the HS-degrading endoglycosidase
(Hennes et al., in press). It may be even more likely that
both properties - increased secretion of proteochondroitin
sulphate and production of the HS-specific endoglycosidase-
influence in an as yet unresolved fashion the selection of
ESb-cells to a favoured metastatic capacity.
It has been reported that colon carcinoma cells produce
more proteochondroitin sulphate than normal colon tissue
(Iozzo & Wight, 1982).
The mere production of proteochondroitin sulphate seems
to be a peculiar property albeit not a stringently occurring
one of cells derived from the haemopoietic system like the
tumour cells studied here. For instance, no HS could be
isolated from lymphocytes of patients with chronic lympho-
cytic leukaemia (Capeau et al., 1978), from lymphocytes of
patients with chronic myelogenous leukaemia (Metcalfe et
al., 1984) and from cloned granulated lymphocytes with
natural killer function and cultured mast cells (Bland et al.,
1984). Also, proteoglycans of thymic lymphocytes consist
largely of proteochondroitin sulphate with only smaller
amounts of proteoheparan sulphate. During in vitro stimula-
tion of thymic lymphocytes the proportion of both cell-
associated and secreted proteochondroitin sulphate was
found to be even increased (Hart, 1982).
Recpntly, it became more evident that proteoglycans pro-
duced by cells of the immune systemlike lymphocytes may
not only have a different structure and distribution but also
may have different biological functions compared to those of
other tissues like epithelium, endothelium or cartilage.
Especially, proteochondroitin sulphates seem to be involved
in immune processes. For example, a proteochondroitin
sulphate localized in granules of natural killer cells is
specifically exocytosed when these cells lyse susceptible
tumour cell targets (MacDermott et al., 1985). Furthermore,
it has been discovered that a 31 kD glycoprotein termed
invariant chain (Ii) which is associated with class II antigens
of the major histocompatibility complex (MHC) is also the
core protein of an MHC class II-associated proteochondroi-
tin sulphate (Sant et al., 1985).
In view of these findings it is now tempting to speculate
how increased secretion of proteochondroitin sulphate by
tumour cells may influence the metastatic process by taking
advantage of cell mediated immune mechanisms. For
instance, Spooncer et al. (1983) reported that haemopoieti-
cally active long-term bone marrow cultures treated with fi-
D-xyloside increase their synthesis and secretion of proteo-
chondroitin sulphate but not that of proteoheparan sulphate.
This stimulation is matched by a preferential increase in
granulocyte-macrophage progenitors (GM-CFC) and in
mature granulocytes. We found that the highly metastatic
cell line ESb and a non-related highly metastatic mouse
BJC-D
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tumour, MDAY-D2, produced constitutively more colony
stimulating activity (predominantly granulocyte CSA) than
the low metastatic cell line Eb which correlated with an
increased tendency to granulocytosis in mice bearing the
respective tumours (Schwartz & Monner, 1986). The
increased stimulation of granulocyte production, possibly
influenced by secretion of proteochondroitin sulphate may
cause disturbances in haemotopoiesis which could give an
advantage for the tumnour cells to survive in the host outside
the primary tumour.
At this point we have no information about the mecha-
nism of proteoglycan secretion by the tumour cells described
here. It may well be that proteoglycans are also included in
extracellular plasma membrane vesicles shedded in an
increased fashion by ESb compared with Eb cells (Barz et
al., 1985).
When comparing metastatic behaviour and expression of
proteoglycans in the Eb/ESb system it has to be considered
that cell lines ESb-MP grows adherently while cell lines Eb
and ESb grow in suspension. Due to this difference proteog-
lycans may be organized in a different way at the cell surface
of ESb-MP-cells which could influence cell-substrate and
cell-cell adhesion. For instance, adherently growing mela-
noma cells restrictively express a proteoglycan on micros-
pikes, a specific microdomain of the cell surface (Garrigues
et al., 1986) which is involved in cell-attachment. Further-
more, we do not know yet how proteoglycans of the Eb/ESb
system are related to each other and if different species of
proteoglycans are produced for cellular expression and secre-
tion. These questions can only be solved by analyzing the
complex nature of the respective proteoglycans. The fine
biochemical structural analysis of the proteoglycans of the
Eb/ESb system is in preparation at present.
References
ALTEVOGT, P., KURNICK, J.T., KIMURA, A.K., BOSSLET, K. &
SCHIRRMACHER, V. (1982). Different expression of Lyt differen-
tiation antigens on cell surface glycoproteins by a murine T-
lymphoma line and its high metastatic variant. Eur. J. Immunol.,
12, 300.
BARZ, D., GOPPELT, M., SZAMEL, M., SCHIRRMACHER, V. &
RESCH, K. (1985). Characterization of cellular and extracellular
plasma membrane vesicles from a non-metastasizing lymphoma
(Eb) and its metastasizing variant (ESb). Biochim. Biophys. Acta,
814, 77.
BENKE, R., LANG, E., KOMITOWSKI, D., MUTO, S. &
SCHIRRMACHER, V. (1988). Changes in tumour cell adhesives
affecting speed of dissemination into blood and internal organs
and mode of metastatic growth. Invas. Metast., 8, 159.
BLAND, K.E., ROSENTHAL, K.L., PLUZNIK, D.H. & 4 others (1984).
Glycosaminoglycan profiles in cloned granulated lymphocytes
with natural killer function and in cultured mast cells: their
potential use as biochemical markers. J. Immunol., 132, 1937.
CAPEAU, J., PICARD, J. & PAUL-GARDAIS, A. (1978). Isolation of
glycosaminoglycans from lymphocytes in chronic lymphoid leuk-
emia. Biomedicine, 28, 124.
COLE, G.J., SCHUBERT, D. & GLASER, L. (1985). Cell-substratum
adhesion in chick neural retina depends upon protein-heparan
sulphate interactions. J. Cell Biol., 100, 1192.
FOGEL, M., ALTEVOGT, P. & SCHIRRMACHER, V. (1983). Metasta-
tic potential severely altered by changes in tumour cell adhesive-
ness and cell surface sialylation. J. Exp. Med., 157, 371.
FRANSSON, L.-A., SJOBERG, I & CHIARUGI, V.P. (1981). Co-poly-
meric glycosaminoglycans in transformed cells. Transformation-
dependent changes in the self-associating properties of cell-
surface heparinsulphate. J. Biol. Chem., 256, 13044.
FRANSSON, L.-A., CARLSTEDT, L., COSTER, L. & MALMSTROM, A.
(1984). Binding of transferrin to the core protein of fibroblast
proteoheparan sulphate. Proc. Nati Acad. Sci. USA, 81, 5657.
FRITZE, L.M.S., REILLY, C.F. & ROSENBERG, R.D. (1985). An
antiproliferative heparan sulphate species produced by post con-
fluent smooth muscle cells. J. Cell Biol., 100, 1041.
GARRIGUES, H.J., LARK, M.W., LARA, S.W., HELLSTROM, I.,
HELLSTROM, K.E. & WIGHT, T.N. (1986). The melanoma pro-
teoglycan: restricted expression on microspikes, a specific micro-
domain of the cell surface. J. Cell Biol., 103, 1699.
GREILING, H., STUHLSATZ, H.W. & TILLMANNS, U. (1984). Chon-
droitin, chondroitin 4-sulphate, chondroitin 6-sulphate, and der-
matan sulphate. In Methods of Enzymatic Analysis, Bergmeyer,
H.U. (ed) p. 60, 3rd edition, vol. 6. Verlag Chemie, Weinheim,
FRG.
GRIESMACHER, A., HENNES, R., KELLER, R. & GREILING, H.
(1987). Proteoglycans from human umbilical vein endothelial
cells. Eur. J. Biochem., 168, 95.
HART, G.W. (1982). Biosynthesis of glycosaminoglycans by thymic
lymphocytes. Effects of mitogenic activation. Biochemistry 24,
6088.
HENNES, R., FRANTZEN, F., KELLER, R., SCHIRRMACHER, V. &
SCHWARTZ, R. Matrix heparan sulphate but not endothelial cell
surface heparan sulphate is degraded by highly metastatic mouse
lymphoma cells. Br. J. Cancer (In press).
HOLLMANN, J., THIEL, J., SCHMIDT, A. & BUDDECKE, E. (1986).
Increased activity of chondroitin sulphate-synthesizing enzymes
during proliferation of arterial smooth muscle cells. Exp. Cell
Res., 167, 484.
IOZZO, R.V. (1985). Biology of disease. Proteoglycans: Structure,
function and role in neoplasia. Lab. Invest., 53, 373.
IOZZO, R.V. & WIGHT, T.N. (1982). Isolation and characterization of
proteoglycans synthesized by human colon and colon carcinoma.
J. Biol. Chem., 257, 11135.
KELLER, K.L., KELLER, J.M. & MOY, J.N. (1980). Heparan sulphates
from Swiss Mouse 3T3 and SV3T3 cells: 0-sulphate difference.
Biochemistry, 19, 2529.
KELLER, R., SILBERT E.J., FURTHMAYR, H. & MADRI, J.A. (1987).
Aortic endothelial cell proteoheparan sulfate. I. Isolation and
characterization of plasmamembrane-associated and extracellular
species. Amer. J. Pathol. 128, 286.
KUCHERLAPATI, R.S., HILWIG, I., GROPP, A. & RUDDLE, F.H.
(1975). Mammalian chromosome identification in interspecific
hybrid cells using 'Hoechst 33258'. Humangenetik, 27, 9.
LANDNER, A.D., FUJI, D.K., GOSPODAROWICZ, D. & REICHARDT,
L.F. (1982). Characterization of a factor that promotes neurite
outgrowth: evidence linking activity to a heparan sulphate pro-
teoglycan. J. Cell Biol., 94, 574.
LATERRA, J., SILBERT, J.E. & CULP, L.A. (1983). Cell surface
heparan sulphate mediates some adhesive responses to glycosam-
ninoglycan-binding matrices, including fibronectin. J. Cell Biol.
96, 112.
LEVITT, D. & HO, P.-L. (1983). Induction of chondroitin sulphate
proteoglycan synthesis and secretion in lymphocytes and mono-
cytes. J. Cell Biol., 97, 351.
MAcDERMOTT, R.P., SCHMIDT, R.E., CAULFIELD, J.P. & 6 others
(1985). Proteoglycans in cell-mediated cytotoxicity. Identification,
localization, and exocytosis of a chondroitin sulphate proteogly-
can from human cloned natural killer cells during target cell
lysis. J. Exp. Med., 162, 1771.
METCALFE, D.D., BLAND, C.E. & WASSERMAN, S.I. (1984). Bioche-
mical and functional characterization of proteoglycans isolated
from basophils of patients with chronic myelogenous leukemia.
J. Immunol., 132, 1943.
ROBINSON, J., VITI, M. & HOOK, M. (1984). Structure and properties
of an under-sulphated heparan sulphate proteoglycan synthesized
by a rat hepatoma cell line. J. Cell Biol., 98, 946.
SANT, A.J., CULLEN, S.E., GIACOLETTO, K.S. & SCHWARTZ, B.D.
(1985). Invariant chain is the core protein of the Ia-associated
chondroitin sulphate proteoglycan. J. Exp. Med., 162, 1916.
SCHIRRMACHER, V., BOSSLET, K., SHANTZ, G., CLAUER &
HJBSCH, D. (1979a). Tumour metastases and cell-mediated
immunity in a model system in DBA/2 mice. IV. Antigenic
differences between a metastasizing variant and the parental
tumour line revealed by cytotoxic T lymphocytes. Int. J. Cancer,
23, 245.
SCHIRRMACHER, V., SHANTZ, G., CLAUER, K., KOMITOWSKI, D.,
ZIMMERMANN, H.-P. & LOHMANN-MATTHES, M.L. (1979b).
Tumour metastases and cell-mediated immunity in a model
system in DBA/2 mice. I. Tumour invasiveness in vitro and
metastasis formation in vivo. Int. J. Cancer, 23, 233.PROTEOGLYCANS OF LOW AND HIGHLY METASTATIC MURINE LYMPHOMAS 575
SCHWARTZ, R., SCHIRRMACHER, V. & MOHLRADT, P.F. (1984).
Glycoconjugates of murine tumour lines with different metastatic
capacities. I. Differences in fucose utlization and in glycoprotein
patterns. Int. J. Cancer, 33, 503.
SCHWARTZ, R., KNIEP, B., MUTHING, J. & MOHLRADT, P.F. (1985).
Glycoconjugates of murine tumour lines with different metastatic
capacities. II Diversity of glycolipid composition. Int. J. Cancer,
36, 601.
SCHWARTZ, R. & MONNER, D.A. (1986). Constitutive production of
colony-stimulating factor by mouse lymphoma cell lines is corre-
lated with granulocytosis in vivo. Exp. Hematol., 14, 615.
SILVESTRI, L., BAKER, J.R., RODEN, L. & STROUD, R.M. (1981). The
Clq inhibitor in serum is a chondroitin 4-sulphate proteoglycan.
J. Biol. Chem., 256, 7383.
SPIRO, R.G. & PARTHASARATHY, N. (1982). Studies on the proteog-
lycan of basement membranes. In New trends in basement
membrane research Kuehn, et al. (eds) p. 87, Raven Press.
SPOONCER, E., GALLAGHER, J.T., KRIZSA, F. & DEXTER, T.M.
(1983). Regulation of haemopoiesis in long-term bone marrow
cultures IV. Glycosaminoglycan synthesis and the stimulation of
haemopoiesis by ,B-D-xylosides. J. Cell Biol. 96, 510.
STAMATOGLOU, S.C. & KELLER, J.M. (1983). Correlation between
cell substrate attachment in vitro and cell surface heparan
sulphate affinity for fibronectin and collagen. J. Cell Biol., 96,
1820.
STUHLSATZ, H.W., HIRTZEL, F., KELLER, R., COSMA, S. &
GREILING, H. (1981). Studies on the polydispersity and heteroge-
neity of proteokeratan sulphate from calf and porcine cornea.
Hoppe-Seyler's Z. Physiol. Chem., 362, 841.
UNDERHILL, C.B. & KELLER, J.M. (1975). A transformation-depen-
dent difference in heparan sulphate associated with the cell
surface. Biochem. Biophys. Res. Com., 63, 448.
VLODAVSKY, I., FUKS, Z., BAR-NER, M., ARIAV, Y. &
SCHIRRMACHER, V. (1983). Lymphoma cell-mediated degrada-
tion of sulphated proteoglycans in the subendothelial extracellu-
lar matrix: relationship to tumour cell metastasis. Cancer Res.,
43, 2704.
WINTERBORNE, D.J. & MORA, P.T. (1981). Cells selected for high
tumourigenicity or transformed by Simian Virus 40 synthesize
heparan sulphate with reduced degree of sulphation. J. Biol.
Chem., 256, 4310.